[212Pb]Pb-ADVC002

[212Pb]Pb-ADVC002 is a targeted alpha radioligand therapy under preclinical development for the treatment of melanoma. It utilizes the radioisotope lead-212 (²¹²Pb), which emits alpha particles to deliver ionizing radiation directly to tumor cells, causing DNA damage and cell death. The drug is part of a new generation of therapeutic radiopharmaceuticals designed for high specificity and potency against cancer cells, with reduced off-target toxicity compared to traditional therapies. Developed by AdvanCell Isotopes, this agent leverages proprietary isotope production technology to ensure reliable supply and effective delivery in targeted alpha therapy applications[1][2][3][9].